Clinical Trials

Sleep and Cognition After Atripla to Stribild Switch

Condition:   HIV
Interventions:   Drug: Stribild;   Drug: Atripla
Sponsors:   University of Hawaii;   Gilead Sciences
Unknown status
Wed, 05 Nov 2014 12:00:00 EST

ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla

Condition:   HIV Infections
Intervention:   Drug: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg
Sponsor:   Gilead Sciences
Completed
Thu, 14 Feb 2008 12:00:00 EST

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

Condition:   Human Immunodeficiency Virus (HIV)
Interventions:   Drug: Doravirine, Tenofovir, Lamivudine;   Drug: ATRIPLA™;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting
Tue, 31 Mar 2015 12:00:00 EDT

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Conditions:   HIV;   HIV Infections
Interventions:   Drug: Stribild;   Drug: Atripla
Sponsor:   Gilead Sciences
Completed
Thu, 26 Mar 2009 12:00:00 EDT

Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients

Condition:   Tuberculosis
Interventions:   Drug: rifapentine (M000473);   Drug: EFZ EMT TDF
Sponsor:   Sanofi
Completed
Fri, 21 Sep 2012 12:00:00 EDT

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)

Condition:   Infection, Human Immunodeficiency Virus I
Interventions:   Drug: Dolutegravir;   Drug: Atripla;   Drug: Abacavir/Lamivudine;   Drug: Abacavir/Lamivudine Placebo;   Drug: Dolutegravir placebo;   Drug: Atripla placebo
Sponsors:   ViiV Healthcare;   Shionogi;   GlaxoSmithKline
Completed
Mon, 20 Dec 2010 12:00:00 EST

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

Condition:   Healthy
Interventions:   Drug: tenofovir, emtricitabine and efavirenz fixed dose tablet;   Drug: tenofovir, emtricitabine and efavirenz tablet added to solution
Sponsors:   University of Alabama at Birmingham;   Bristol-Myers Squibb
Completed
Tue, 17 Mar 2009 12:00:00 EDT

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Condition:   HIV
Intervention:   Drug: ATRIPLA
Sponsor:   Anna Cruceta
Completed
Tue, 29 Jan 2013 12:00:00 EST

Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

Conditions:   HIV;   AIDS;   Sleep Disorders
Intervention:   Drug: Stribild
Sponsors:   Midtown Medical Center, Tampa, FL;   Gilead Sciences
Completed
Mon, 22 Jun 2015 12:00:00 EDT

Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

Condition:   HIV-1
Interventions:   Drug: efavirenz + emtricitabina + tenofovir;   Drug: rilpivirina + emtricitabina + tenofovir
Sponsors:   Hospital Universitari Vall d'Hebron Research Institute;   Gilead Sciences
Completed
Fri, 11 Sep 2015 12:00:00 EDT

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Condition:   HIV-1-infection
Interventions:   Drug: B/F/TAF;   Drug: Atripla;   Drug: B/F/TAF Placebo;   Drug: Atripla Placebo
Sponsors:   University of Alberta;   Gilead Sciences;   University of British Columbia
Completed
Tue, 22 May 2018 12:00:00 EDT

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Conditions:   HIV;   HIV Infections
Interventions:   Drug: Stribild;   Drug: Atripla;   Drug: Stribild Placebo;   Drug: Atripla Placebo
Sponsor:   Gilead Sciences
Completed
Tue, 30 Mar 2010 12:00:00 EDT

Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera

Condition:   HIV
Interventions:   Drug: Tenofovir disoproxil/emtricitabine/rilpivirine;   Drug: Tenofovir disoproxil/emtricitabine/efavirenz
Sponsor:   Sheba Medical Center
Terminated
Mon, 18 May 2015 12:00:00 EDT

HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women

Condition:   HIV
Intervention:   Drug: Atripla or Stribild
Sponsors:   Fred Hutchinson Cancer Research Center;   Asociación Civil Impacta Salud y Educación, Peru;   NGO Via Libre;   Epicentro, Barranco District, Peru
Completed
Thu, 21 Mar 2013 12:00:00 EDT

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

Conditions:   HIV-1;   Central Nervous System
Interventions:   Drug: Doravirine, Tenofovir, Lamivudine - Blinded;   Drug: Doravirine, Tenofovir, Lamivudine - Open-Label;   Drug: ATRIPLA^TM;   Drug: Placebo to ATRIPLA™;   Drug: Placebo to Doravirine, Tenofovir, Lamivudine
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting
Mon, 11 Jan 2016 12:00:00 EST

Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning

Conditions:   Neurocognitive Decline;   HIV Associated Neurocognitive Disorder
Intervention:   Drug: Eviplera
Sponsors:   UMC Utrecht;   Gilead Sciences
Completed
Thu, 04 Dec 2014 12:00:00 EST

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Condition:   HIV Infections
Interventions:   Drug: Kaletra + Isentress;   Drug: Atripla
Sponsors:   University of California, San Diego;   California HIV/AIDS Research Program;   Merck Sharp & Dohme Corp.;   Abbott
Completed
Tue, 16 Sep 2008 12:00:00 EDT

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial

Condition:   HIV Infections
Interventions:   Drug: Atripla;   Drug: Kivexa plus Sustiva
Sponsor:   Gilead Sciences
Completed
Thu, 14 Feb 2008 12:00:00 EST

PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers

Conditions:   HIV Infection;   HIV Infections
Intervention:   Drug: Atripla®
Sponsor:   St Stephens Aids Trust
Completed
Thu, 22 Apr 2010 12:00:00 EDT

SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms

Condition:   HIV
Intervention:   Drug: Eviplera
Sponsors:   St Stephens Aids Trust;   Gilead Sciences
Completed
Wed, 19 Aug 2015 12:00:00 EDT

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

Condition:   HIV
Interventions:   Drug: atripla;   Drug: darunavir ritonavir raltegravir
Sponsor:   East Carolina University
Unknown status
Thu, 28 Apr 2011 12:00:00 EDT

Atripla to Raltegravir Switch Study for CNS Toxicity

Condition:   HIV Infection
Intervention:   Drug: Truvada/Raltegravir
Sponsor:   St Stephens Aids Trust
Completed
Mon, 06 Sep 2010 12:00:00 EDT

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

Condition:   HIV-1 Infection
Interventions:   Drug: EFV/FTC/TDF;   Drug: Calcium Carbonate;   Drug: Vitamin D3;   Drug: Placebo for calcium carbonate;   Drug: Placebo for vitamin D3
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed
Wed, 27 Jul 2011 12:00:00 EDT

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

Condition:   HIV-1 Infections
Interventions:   Drug: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily;   Drug: TDF/FTC + Efavirenz (Atripla) Once-Daily
Sponsors:   Rush University Medical Center;   Merck Sharp & Dohme Corp.
Withdrawn
Fri, 25 Sep 2009 12:00:00 EDT

Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens

Conditions:   HIV Infections;   Adherence
Intervention:  
Sponsor:   University of California, San Francisco
Completed
Sun, 01 Nov 2009 12:00:00 EDT

Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan

Condition:   HIV Infections
Intervention:   Drug: 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)
Sponsor:   Yu-Jay Corp.
Completed
Mon, 23 Jul 2018 12:00:00 EDT

A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine

Condition:   HIV
Intervention:   Drug: tenofovir/emtricitabine/rilpivirine
Sponsor:   St Stephens Aids Trust
Completed
Fri, 05 Oct 2012 12:00:00 EDT

A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells

Conditions:   HIV Infections;   Acquired Immune Deficiency Syndrome
Interventions:   Drug: Raltegravir plus Truvada;   Drug: Atripla
Sponsors:   Community Research Initiative of New England;   Merck Sharp & Dohme Corp.
Withdrawn
Mon, 02 Aug 2010 12:00:00 EDT

Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity

Condition:   HIV
Intervention:   Drug: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
Sponsors:   St Stephens Aids Trust;   ViiV Healthcare
Unknown status
Fri, 07 Nov 2014 12:00:00 EST

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

Condition:   HIV-1 Infection
Interventions:   Drug: Dolutegravir;   Drug: Tenofovir Alafenamide;   Drug: Truvada;   Drug: Atripla
Sponsor:   Professor Francois Venter
Active, not recruiting
Thu, 20 Apr 2017 12:00:00 EDT

Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)

Condition:   HIV Infections
Interventions:   Drug: Tenofovir/Emtricitabine (Truvada) and Nevirapine;   Drug: Tenofovir/Emtricitabine/Efavirenz (Atripla);   Drug: Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia);   Drug: Tenofovir/Emtricitabine (Truvada) and Zidovudine
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba;   Gilead Sciences;   Merck Sharp & Dohme Corp.
Completed
Thu, 13 Dec 2007 12:00:00 EST

Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients

Condition:   HIV Infections
Interventions:   Drug: efavirenz/emtricitabin/tenofovir;   Drug: lopinavir/ritonavir
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   Abbott;   Gilead Sciences
Completed
Mon, 27 Jul 2009 12:00:00 EDT

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Condition:   HIV-1 Infection
Interventions:   Drug: FTC/RPV/TAF;   Drug: EFV/FTC/TDF Placebo;   Drug: EFV/FTC/TDF;   Drug: FTC/RPV/TAF Placebo
Sponsor:   Gilead Sciences
Completed
Mon, 26 Jan 2015 12:00:00 EST

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Condition:   Acquired Immune Deficiency Syndrome
Interventions:   Drug: Lopinavir 400 mg/ritonavir 100 mg;   Drug: Efavirenz
Sponsors:   Rush University Medical Center;   University of Chicago;   University of Illinois at Chicago;   Ruth M. Rothstein CORE Center;   Abbott;   Gilead Sciences
Terminated
Mon, 20 Oct 2008 12:00:00 EDT

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

Condition:   HIV Disease
Intervention:   Drug: Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
Sponsors:   Massachusetts General Hospital;   Brigham and Women's Hospital;   Gilead Sciences
Completed
Wed, 28 Aug 2013 12:00:00 EDT

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

Conditions:   HIV;   HIV-associated Neurocognitive Disorder;   Neurotoxicity
Intervention:   Drug: Raltegravir
Sponsors:   Massachusetts General Hospital;   Merck Sharp & Dohme Corp.
Completed
Thu, 07 Nov 2013 12:00:00 EST

Universal Use of EFV-TDF-FTC and AZT-3TC-LPV/r Combinations for HIV-1 PMTCT in Pregnant and Breastfeeding Women : a Phase 3 Trial

Conditions:   HIV Infection;   Pregnancy;   Breastfeeding;   HIV Infections
Interventions:   Drug: Efavirenz-Tenofovir-Emtricitabine;   Drug: Zidovudine-Lamivudine-Lopinavir/Ritonavir
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   Gilead Sciences;   Merck Sharp & Dohme Corp.;   GlaxoSmithKline;   Abbott
Withdrawn
Thu, 09 Jul 2009 12:00:00 EDT

LAAM-HAART PET Imaging

Condition:   Healthy Volunteers
Interventions:   Radiation: [11c] LAAM;   Drug: Ritonavir;   Drug: Efavirenz
Sponsor:   Washington University School of Medicine
Completed
Thu, 05 Sep 2013 12:00:00 EDT

Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects

Conditions:   Impaired Cognition;   Depression/Anxiety;   Poor Quality Sleep;   Quality of Life;   HIV-1 Infection
Interventions:   Drug: Immediate switch to TDF/FTC/RPV;   Drug: Switch to TDF/FTC/RPV after 24 weeks
Sponsors:   Azienda Ospedaliera San Gerardo di Monza;   Gilead Sciences
Completed
Wed, 22 Jan 2014 12:00:00 EST

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

Condition:   HIV Infections
Interventions:   Drug: Enfuvirtide;   Drug: Efavirenz, lamivudine, and tenofovir
Sponsor:   University of Maryland, Baltimore
Completed
Tue, 27 Jun 2006 12:00:00 EDT

Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3

Condition:   HIV-1 Infection
Interventions:   Device: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray;   Drug: ART (Atripla, Truvada, Efavirenz, Combivir);   Drug: Rifampin, isoniazid, pyrazinamide, ethambutol
Sponsor:   ANRS, Emerging Infectious Diseases
Completed
Fri, 07 Feb 2014 12:00:00 EST

Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

Condition:   HIV
Interventions:   Drug: Tenofovir;   Drug: Zidovudine
Sponsors:   Tufts University;   Christian Medical College, Vellore, India
Completed
Wed, 26 Sep 2012 12:00:00 EDT

Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma

Conditions:   HIV-1 Infection;   Kaposi's Sarcoma
Interventions:   Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate;   Drug: etoposide
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed
Wed, 11 May 2011 12:00:00 EDT

Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir

Condition:   Healthy
Intervention:   Drug: Efavirenz, tenofovir disoproxil fumarate and emtricitabine
Sponsor:   Laboratorio Elea Phoenix S.A.
Completed
Fri, 13 Oct 2017 12:00:00 EDT

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants

Conditions:   HIV-1-infection;   Tuberculosis
Interventions:   Drug: Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid;   Drug: Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
Sponsors:   Willem Daniel Francois Venter;   University of Cape Town
Completed
Tue, 09 Jun 2020 12:00:00 EDT

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

Condition:   HIV
Interventions:   Drug: Tenofovir/emtricitabine;   Drug: Tenofovir/emtricitabine/efavirenz;   Drug: Raltegravir
Sponsors:   Indiana University;   Merck Sharp & Dohme Corp.
Completed
Wed, 05 Jan 2011 12:00:00 EST

Clinical Trial of CNS-targeted HAART (CIT2)

Condition:   HIV Infections
Intervention:   Drug: FDA Approved Antiretroviral Therapy (see list below)
Sponsors:   University of California, San Diego;   National Institutes of Health (NIH);   National Institute of Mental Health (NIMH)
Completed
Wed, 27 Feb 2008 12:00:00 EST

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

Condition:   Human Immunodeficiency Virus
Intervention:   Drug: bictegravir/emtricitabine/tenofovir alafenamide
Sponsors:   Midland Research Group, Inc.;   Gilead Sciences
Completed
Wed, 18 Apr 2018 12:00:00 EDT

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Condition:   HIV
Interventions:   Drug: Efavirenz;   Drug: tenofovir /emtricitabine;   Drug: tenofovir/lamivudine;   Drug: lamivudine/zidovudine;   Drug: Rifinah or local generics
Sponsors:   St Stephens Aids Trust;   Mylan Inc.;   United States Agency for International Development (USAID)
Unknown status
Thu, 14 Jul 2016 12:00:00 EDT

Interaction With HIV Antiretroviral Agents

Condition:   HIV-DDI
Interventions:   Drug: Riociguat (Adempas, BAY 63-2521);   Drug: ATRIPLA;   Drug: COMPLERA;   Drug: STRIBILD;   Drug: TRIUMEQ;   Drug: Antiretroviral protease inhibitor
Sponsor:   Bayer
Completed
Tue, 22 Sep 2015 12:00:00 EDT

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Condition:   HIV Infections
Interventions:   Drug: Emtricitabine (FTC);   Drug: Tenofovir Disoproxil Fumarate (TDF);   Drug: Efavirenz (EFV);   Drug: FTC/TDF;   Drug: FTC/TDF/EFV;   Drug: Lamivudine/zidovudine
Sponsor:   Gilead Sciences
Completed
Mon, 30 May 2005 12:00:00 EDT

The Mochudi Prevention Project ART Protocol

Condition:   HIV Infections
Intervention:   Drug: highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine
Sponsors:   Harvard School of Public Health;   National Institute of Allergy and Infectious Diseases (NIAID)
Terminated
Tue, 24 Apr 2012 12:00:00 EDT

Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV);   Drug: tenofovir/emtricitabine (TDF/FTC);   Drug: Atazanavir (ATV);   Drug: Ritonavir;   Procedure: Phlebotomy
Sponsors:   University of North Carolina, Chapel Hill;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed
Wed, 11 Aug 2010 12:00:00 EDT

Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence

Condition:   HIV Infection
Interventions:   Drug: Immediate ARV treatment initiation with TDF/FTC/EFV;   Other: South African recommendation guided ARV (TDF/FTC/EFV) initiation
Sponsors:   ANRS, Emerging Infectious Diseases;   Africa Centre For Health and Population Studies;   University of KwaZulu
Completed
Fri, 13 Jan 2012 12:00:00 EST

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Condition:   HIV Infection
Interventions:   Drug: Atripla (r);   Drug: Efavirenz;   Drug: Truvada;   Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDC;   Drug: Rifampin/isoniazid FDC;   Drug: Isoniazid
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Completed
Mon, 27 Jun 2011 12:00:00 EDT

Immune Responses in Patients Treated With Raltegravir

Condition:   HIV Infections
Intervention:   Biological: Various vaccines
Sponsors:   McGill University Health Centre/Research Institute of the McGill University Health Centre;   Merck Sharp & Dohme Corp.
Withdrawn
Wed, 05 Nov 2008 12:00:00 EST

Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women

Conditions:   HIV;   Contraception
Interventions:   Drug: Levonorgestrel;   Drug: Efavirenz
Sponsors:   University of Nebraska;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Infectious Diseases Institute, Uganda;   University of Liverpool;   Feinberg School of Medicine, Northwestern University
Completed
Wed, 30 Mar 2016 12:00:00 EDT

A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

Conditions:   HIV;   Contraception
Interventions:   Drug: Levonorgestrel;   Drug: Nevirapine;   Drug: Efavirenz
Sponsors:   University of Nebraska;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Makerere University;   University of Liverpool
Completed
Tue, 12 Feb 2013 12:00:00 EST

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Conditions:   Hepatitis C;   HIV
Interventions:   Drug: SOF;   Drug: EFV/FTC/TDF;   Drug: EFV;   Drug: ZDV/3TC;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: DRV;   Drug: RAL;   Drug: PEG;   Drug: RBV
Sponsor:   Gilead Sciences
Completed
Thu, 29 Mar 2012 12:00:00 EDT

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Condition:   HIV-1 Infection
Interventions:   Drug: STB;   Drug: TVD;   Drug: ATR;   Drug: RTV;   Drug: ATV;   Drug: ABC/3TC;   Drug: Iohexol
Sponsor:   Gilead Sciences
Completed
Tue, 23 Sep 2014 12:00:00 EDT

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Conditions:   HIV;   HIV Infections
Interventions:   Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: EFV/FTC/TDF;   Drug: RTV;   Drug: ATV;   Drug: FTC/TDF;   Drug: COBI
Sponsor:   Gilead Sciences
Completed
Thu, 21 Mar 2013 12:00:00 EDT

Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS

Condition:   HIV-1 Infection
Interventions:   Drug: Etoposide (ET);   Drug: Bleomycin and Vincristine (BV);   Drug: Paclitaxel (PTX);   Drug: Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
Sponsors:   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   National Cancer Institute (NCI);   National Institute of Dental and Craniofacial Research (NIDCR);   AIDS Malignancy Consortium
Completed
Thu, 15 Sep 2011 12:00:00 EDT

Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men

Conditions:   HIV Infection;   Cardiovascular Risk;   HIV Infections
Interventions:   Other: Omega-3 study meal;   Other: Saturated fat study meal
Sponsor:   Tufts University
Completed
Wed, 18 Feb 2009 12:00:00 EST

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

Condition:   HIV Infections
Intervention:   Drug: Intermitent Dosing
Sponsors:   Community Research Initiative of New England;   The Campbell Foundation
Completed
Thu, 21 Dec 2006 12:00:00 EST

Raltegravir Activity In Lymphoid Tissues

Conditions:   HIV Infection;   HIV Infections
Interventions:   Drug: Efavirenz + Tenofovir DF/Emtricitabine;   Drug: Raltegravir + Tenofovir DF/Emtricitabine;   Procedure: Colonoscopy with biopsies;   Procedure: Inguinal Lymph Node Excision
Sponsors:   University of Minnesota;   Merck Sharp & Dohme Corp.
Withdrawn
Wed, 18 Mar 2009 12:00:00 EDT